Future Science Group
Browse
Supplementary Figure 4.jpg (488.85 kB)

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 4

Download (488.85 kB)
figure
posted on 2022-11-22, 16:37 authored by Chenyue Zhang, Kai Wang, Jiamao Lin, Haiyong Wang

Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor Supplementary Figure 4

Funding

This study was supported jointly by Special Funds for Taishan Scholars Project (grant no. tsqn201812149) and the Academic Promotion Program of Shandong First Medical University (2019RC004). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

History

Usage metrics

    Future Oncology

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC